MiMedx Group Inc
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines,… Read more
MiMedx Group Inc (MDXG) - Net Assets
Latest net assets as of September 2025: $238.95 Million USD
Based on the latest financial reports, MiMedx Group Inc (MDXG) has net assets worth $238.95 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($318.99 Million) and total liabilities ($80.04 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $238.95 Million |
| % of Total Assets | 74.91% |
| Annual Growth Rate | 84.12% |
| 5-Year Change | 111.24% |
| 10-Year Change | 78.82% |
| Growth Volatility | 297.59 |
MiMedx Group Inc - Net Assets Trend (2006–2024)
This chart illustrates how MiMedx Group Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for MiMedx Group Inc (2006–2024)
The table below shows the annual net assets of MiMedx Group Inc from 2006 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $193.11 Million | +35.31% |
| 2023-12-31 | $142.72 Million | +91.55% |
| 2022-12-31 | $74.51 Million | -19.52% |
| 2021-12-31 | $92.58 Million | +1.27% |
| 2020-12-31 | $91.42 Million | +84.11% |
| 2019-12-31 | $49.66 Million | 0.00% |
| 2018-12-31 | $49.66 Million | -32.71% |
| 2017-12-31 | $73.80 Million | -44.51% |
| 2016-12-31 | $133.00 Million | +23.16% |
| 2015-12-31 | $107.99 Million | +20.89% |
| 2014-12-31 | $89.33 Million | +21.42% |
| 2013-12-31 | $73.57 Million | +267.71% |
| 2012-12-31 | $20.01 Million | +68.18% |
| 2011-12-31 | $11.90 Million | +95.01% |
| 2010-12-31 | $6.10 Million | +0.47% |
| 2009-12-31 | $6.07 Million | -57.33% |
| 2008-12-31 | $14.23 Million | +40074.16% |
| 2007-12-31 | $-35.60K | -1191.29% |
| 2006-12-31 | $3.26K | -- |
Equity Component Analysis
This analysis shows how different components contribute to MiMedx Group Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 8982139600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $147.00K | 0.08% |
| Other Components | $284.22 Million | 147.18% |
| Total Equity | $193.11 Million | 100.00% |
MiMedx Group Inc Competitors by Market Cap
The table below lists competitors of MiMedx Group Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shanxi Huaxiang Group Co Ltd
SHG:603112
|
$478.20 Million |
|
Supreme Petrochem Limited
NSE:SPLPETRO
|
$478.27 Million |
|
GSP Automotive Group Wenzhou Co Ltd
SHG:605088
|
$478.39 Million |
|
Vatti Corp Ltd
SHE:002035
|
$478.47 Million |
|
BayWa Aktiengesellschaft
F:BYW
|
$478.06 Million |
|
AmRest Holdings SE
OTCGREY:ARHOF
|
$477.90 Million |
|
Happinet Corporation
PINK:HAPYF
|
$477.57 Million |
|
Nuvoton Technology Corp
TW:4919
|
$477.41 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in MiMedx Group Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 142,717,000 to 193,107,000, a change of 50,390,000 (35.3%).
- Net income of 42,419,000 contributed positively to equity growth.
- Share repurchases of 2,641,000 reduced equity.
- Other comprehensive income increased equity by 239,047,000.
- Other factors decreased equity by 228,435,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $42.42 Million | +21.97% |
| Share Repurchases | $2.64 Million | -1.37% |
| Other Comprehensive Income | $239.05 Million | +123.79% |
| Other Changes | $-228.44 Million | -118.29% |
| Total Change | $- | 35.31% |
Book Value vs Market Value Analysis
This analysis compares MiMedx Group Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.37x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 7588.33x to 3.37x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-12-31 | $0.00 | $4.36 | x |
| 2007-12-31 | $0.00 | $4.36 | x |
| 2008-12-31 | $2.46 | $4.36 | x |
| 2009-12-31 | $0.16 | $4.36 | x |
| 2010-12-31 | $0.10 | $4.36 | x |
| 2011-12-31 | $0.16 | $4.36 | x |
| 2012-12-31 | $0.25 | $4.36 | x |
| 2013-12-31 | $0.76 | $4.36 | x |
| 2014-12-31 | $0.79 | $4.36 | x |
| 2015-12-31 | $0.95 | $4.36 | x |
| 2016-12-31 | $1.18 | $4.36 | x |
| 2017-12-31 | $0.64 | $4.36 | x |
| 2018-12-31 | $0.46 | $4.36 | x |
| 2019-12-31 | $0.47 | $4.36 | x |
| 2020-12-31 | $0.84 | $4.36 | x |
| 2021-12-31 | $0.84 | $4.36 | x |
| 2022-12-31 | $0.66 | $4.36 | x |
| 2023-12-31 | $0.98 | $4.36 | x |
| 2024-12-31 | $1.30 | $4.36 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently MiMedx Group Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 21.97%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 12.16%
- • Asset Turnover: 1.32x
- • Equity Multiplier: 1.37x
- Recent ROE (21.97%) is above the historical average (-61.93%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | -513.12% | 0.00% | 0.00x | 4.25x | $-17.06K |
| 2007 | 0.00% | 0.00% | 0.00x | 0.00x | $-35.30K |
| 2008 | -122.08% | 0.00% | 0.00x | 1.07x | $-18.79 Million |
| 2009 | -196.30% | 0.00% | 0.00x | 1.60x | $-12.53 Million |
| 2010 | -187.19% | -1447.60% | 0.11x | 1.21x | $-12.03 Million |
| 2011 | -85.69% | -131.36% | 0.29x | 2.28x | $-11.38 Million |
| 2012 | -38.30% | -28.32% | 0.77x | 1.76x | $-9.66 Million |
| 2013 | -5.59% | -6.95% | 0.70x | 1.15x | $-11.47 Million |
| 2014 | 6.96% | 5.26% | 1.08x | 1.22x | $-2.71 Million |
| 2015 | 27.27% | 15.72% | 1.38x | 1.26x | $18.65 Million |
| 2016 | 9.00% | 4.89% | 1.27x | 1.45x | $-1.33 Million |
| 2017 | 87.71% | 20.16% | 2.65x | 1.64x | $57.35 Million |
| 2018 | -60.37% | -8.35% | 2.92x | 2.47x | $-34.94 Million |
| 2019 | -60.37% | -8.35% | 2.92x | 2.47x | $-34.94 Million |
| 2020 | -53.91% | -19.85% | 1.23x | 2.21x | $-58.43 Million |
| 2021 | -13.29% | -5.08% | 1.29x | 2.03x | $-21.56 Million |
| 2022 | -40.53% | -11.27% | 1.56x | 2.30x | $-37.65 Million |
| 2023 | 47.25% | 20.98% | 1.34x | 1.67x | $53.17 Million |
| 2024 | 21.97% | 12.16% | 1.32x | 1.37x | $23.11 Million |
Industry Comparison
This section compares MiMedx Group Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| MiMedx Group Inc (MDXG) | $238.95 Million | -513.12% | 0.33x | $478.13 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |